Fresenius Kabi issues separate recalls for drugs made at Illinois plant

A Fresenius Kabi worker
A Fresenius Kabi worker

German generics unit Fresenius Kabi issued two separate voluntary recalls for injectables produced at its plant in Illinois.

A Class II recall was put out by the company and posted on the FDA’s enforcement page for more than 96,000 units of the muscle relaxant cisatracurium besylate that are administered intravenously. The firm found the product had an incorrect statement of “preservative free” on the individual carton label. The vial label and outer carton label contain the correct statement of 0.9% benzyl alcohol added as a preservative.

A Class III recall was issued for more than 48,000 units of the antipsychotic injectable drug haloperidol decanoate in 50 milligram doses due to an impurity out-of-specification result.

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

Both drugs are prescription-only products.

Back in 2012 and 2013, the generics maker had a spate of FDA warning letters for plants in Grand Island, NY, Kalyani, India, and Puerto Rico. It upgraded its plant in New York.

- access the FDA posting here

Read more on

Suggested Articles

Higher operating costs were behind a 17% slide in pretax profits last year at Allergan’s Mayo, Ireland, facility that produces Botox.

After a global scare over Zantac contamination, generic metformin could be next in line as regulators test for possible carcinogen contamination.

PCI Pharma Services debuts expansion of its plant in Rockford, Illinois.